CCHT(SZ:000661) Bei Jing Shang Bao·2025-10-31 13:12Core Viewpoint - Changchun High-tech (000661) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial application of GenSci134 injection, a self-developed biological product aimed at treating growth hormone deficiency (GHD) [1] Company Summary - Changchun Jinsai Pharmaceutical's GenSci134 injection is classified as a Class 1 therapeutic biological product [1] - The drug is intended for the treatment of GHD, including adult growth hormone deficiency (AGHD), pediatric growth hormone deficiency (PGHD), and non-GHD conditions such as idiopathic short stature (ISS) [1] - The current application specifically targets children experiencing growth retardation due to endogenous growth hormone deficiency (PGHD) [1]